Compare · HUM vs ISR
HUM vs ISR
Side-by-side comparison of Humana Inc. (HUM) and IsoRay Inc. (ISR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and ISR operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $39.42B, about 771.5x ISR ($51.1M).
- HUM has hit the wire 6 times in the past 4 weeks while ISR has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 1 for ISR).
- Company
- Humana Inc.
- IsoRay Inc.
- Price
- $328.39+7.46%
- $0.38-1.03%
- Market cap
- $39.42B
- $51.1M
- 1M return
- +38.75%
- -
- 1Y return
- +42.07%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 1
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
IsoRay Inc.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Latest HUM
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
- Humana upgraded by Deutsche Bank with a new price target
- Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness
- Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)
- President & CEO Rechtin James A. was granted 35,633 units of Humana Common (SEC Form 4)
Latest ISR
- IsoRay Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)
- Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)
- Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)
- Williamson Robert F Iii bought $25,478 worth of shares (51,996 units at $0.49), increasing direct ownership by 220% to 75,676 units (SEC Form 4)
- SEC Form D filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 424B5 filed by IsoRay Inc.